Management of AIDS-related Kaposi's sarcoma (Q36724341)

15 August 2017

1 reference

title

Management of AIDS-related Kaposi's sarcoma (English)

1 reference

15 August 2017

Giuseppe Di Lorenzo

1

1 reference

15 August 2017

Panagiotis A Konstantinopoulos

2

1 reference

15 August 2017

Liron Pantanowitz

3

1 reference

15 August 2017

Rossella Di Trolio

4

1 reference

15 August 2017

Sabino De Placido

5

1 reference

15 August 2017

Bruce J Dezube

6

1 reference

15 August 2017

1 February 2007

1 reference

Lancet Oncology Commission

15 August 2017

1 reference

15 August 2017

8

1 reference

15 August 2017

2

1 reference

15 August 2017

167-176

1 reference

Trends in cancer risk among people with AIDS in the United States 1980-2002.

15 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Kaposi's sarcoma in patients with and without human immunodeficiency virus infection, in a tertiary referral centre in Kenya

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Treating Kaposi's lesions in the HIV-infected patient

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Kaposi's sarcoma of internal organs. A multiparameter study of 86 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Histological features of kaposi sarcoma in a patient receiving highly active antiviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

How does HAART lead to the resolution of Kaposi's sarcoma?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Kaposi's sarcoma--an update

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Differential Impact of Combination Antiretroviral Therapy in Preventing Kaposi's Sarcoma With and Without Visceral Involvement

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Immune reconstitution inflammatory syndrome in HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma during potent antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Palliative treatment of epidemic Kaposi sarcoma of the feet

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

The role of radiation therapy in the management of HIV-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Epidemic and endemic Kaposi's sarcoma: a comparison of outcomes and survival after radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Radiotherapy in the management of epidemic Kaposi's sarcoma: a retrospective study of 643 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Radiotherapy in the management of Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Intralesional vinblastine vs. 3% sodium tetradecyl sulfate for the treatment of oral Kaposi's sarcoma. A double blind, randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Cryotherapy for Cutaneous Kaposi??s Sarcoma (KS) Associated with Acquired Immune Deficiency Syndrome (AIDS)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Photofrin photodynamic therapy for treatment of AIDS-related cutaneous Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Advantages of liposomal delivery systems for anthracyclines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Effect of treatment on health-related quality of life in acquired immunodeficiency syndrome (AIDS)-related Kaposi's sarcoma: a randomized trial of pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Treatment of HIV-1-associated Kaposi's sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Liposomal encapsulated anti-cancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Serologic and molecular evidence of human herpesvirus 8 activation in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Weekly docetaxel is safe and effective in the treatment of advanced-stage acquired immunodeficiency syndrome-related Kaposi sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Docetaxel in anthracycline-pretreated AIDS-related Kaposi's sarcoma: a retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Efficacy of low-dose interferon with antiretroviral therapy in Kaposi's sarcoma: a randomized phase II AIDS clinical trials group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials Network study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Liposomal pegylated doxorubicin versus low-dose recombinant interferon Alfa-2a in the treatment of advanced classic Kaposi's sarcoma; retrospective analysis of three German centers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Kaposi's sarcoma-associated human herpesvirus-8 encodes homologues of macrophage inflammatory protein-1 and interleukin-6.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Vascular endothelial growth factor receptor-3 (VEGFR-3): a marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Human herpesvirus-8-transformed endothelial cells have functionally activated vascular endothelial growth factor/vascular endothelial growth factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Vascular Endothelial Growth Factor-C (VEGF-C) and its Receptors KDR and flt-4 are Expressed in AIDS-Associated Kaposi’s Sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/ KDR.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Activity of thalidomide in AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Regulation of PDGF-B and PDGF receptor expression in the pathogenesis of Kaposi's sarcoma in AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Expression of platelet-derived growth factor and its receptor in AIDS-related Kaposi sarcoma in vivo suggests paracrine and autocrine mechanisms of tumor maintenance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Kaposi's sarcoma-associated herpesvirus-induced upregulation of the c-kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Imatinib-induced regression of AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Preliminary communication: matrix metalloproteinases in Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Constitutive release of metalloproteinase-9 (92-kd type IV collagenase) by Kaposi's sarcoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Development of matrix metalloproteinase inhibitors in cancer therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Signal transduction targets in Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Sirolimus for Kaposi's sarcoma in renal-transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

Unusual Sites of Malignancies: CASE 3. AIDS-related Kaposi's sarcoma of the gastrointestinal tract

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970036-0

7 January 2021

10.1016/S1470-2045(07)70036-0

Identifiers

DOI

1 reference

15 August 2017

1 reference